FDA Approves Lynparza-Mvasi Combo as Maintenance Therapy for Advanced Ovarian Cancer

Published by Jason Butcher on

The FDA approved new indications for olaparib (Lynparza, AstraZeneca) and bevacizumab-awwb (Mvasi, Amgen) to be used in combination for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Read More…

Categories: Uncategorized

Related Posts

Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care

Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…

FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication

The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…

Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women

Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…